NCT06626620View on ClinicalTrials.gov

Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma

PHASE3CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions

Acute Exacerbation of Asthma

Interventions

DRUG

Magnesium Sulphate infusion

Received IV magnesium sulfate (50 mg/kg up to a maximum dose of 2 g) administered over 20 minutes

DRUG

Terbutaline Infusion

Received IV terbutaline (10 mcg/kg bolus followed by a continuous infusion of 0.4 mcg/kg/min) for up to 4 hours

Trial Locations (1)

Unknown

Nishtar Hospital, Multan

All Listed Sponsors

collaborator

Nishtar Medical University

OTHER

lead

Muhammad Aamir Latif

OTHER

NCT06626620 - Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma | Biotech Hunter | Biotech Hunter